Recombinant influenza virus vector carrier vaccine (tuberculosis) - Polymun Scientific

Drug Profile

Recombinant influenza virus vector carrier vaccine (tuberculosis) - Polymun Scientific

Alternative Names: influenza A virus vector carrier vaccine (tubrculosis) - Polymun Scientific

Latest Information Update: 22 Apr 2016

Price : $50

At a glance

  • Originator Polymun Scientific
  • Class Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Tuberculosis

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 22 Apr 2016 Preclinical trials in Tuberculosis (Prevention) in Austria (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top